Aaaah yes. So let's have another company who has huge investors like the level of major banks and the like.
MBOT
dozens of patents in the US, and dozens of foreign companies.
Still working on their product. Another reverse stock split. They are a big board company.
The reality is, that even with financial backing, if there is no source of revenue, if IMUN somehow ended up on the big board, it would face rapid stock decline, and have to do more reverse stock splits to keep from being listed.
As Hopeful stated, we do have stake in a company who may have an evaluation of $2.5 M, but that evaluation will not attract retail investors to a company not making revenue.
Also keep in mind that it will be a long time before FDA approval of LDN for Cytocom.
If Cytocom's path is to be a public company, it still needs financial backing and would still need to file an S-1 to be a public compamy. I am told that is about a 3 month process.
Then you have the long exhausting interview process to get qualified candidates for the 2b/3a Chrone's trial. Not sure how many months that will take, the all the data has to be submitted to the FDA. Then the FDA will take the time, they take to issue their decision.
Now if the trials go outstanding, the stock price should shoot through the roof, even before FDA approval.
So, devil's advocate...during this time Cytocom will not be generating any revenue. Depending on how the new Cytocom CEO is about transparency, telling the LDN story, and promoting retail trading, will depend on how the stock price fluctuates.
I just do not think IMUN's stock will be able to maintain off a 10% evaluation of a company that is not making money, and IMUN is not making money.
Then we ask ourselves this...if both companies uplist, why would a retail investor, invest in a company, if they still aren't generating income, and their evaluation is based on 10% of a company that I can directly buy stock in? Why would I invest in IMUN, when I can directly invest in Cytocom and see the 90% gain instead of the 10%.
Realistically, doing the math, and the US patents for LDN, I think Cytocom will easily hit $25 a share. It is hard to say if IMUN will ever hit $10 a share, because they are still dealing with getting things accomplished in a 3rd world country where anything can change at any moment.
Example: some friends of mine were adopting a little girl from China. Now, the adoption procedure is clear cut, at least on paper. But yet at every step of the way, they were told that "many things can happen to slow the paperwork along the way, or maybe it will be lost or sent to the wrong place.
Basically, if they did not give kickbacks to almost every person along the way, something could happen to there paperwork. So basically, the adoption took an extra year, to a tune of an extra $10,000 to get this little girl to the USA.
The reason I mention this story, is it has been years and years, and there is still no revenue being generated from sales of LDN IN Africa. Yes, I understand there was 250,000 pills shipped, but there has been no news of payment.
Like was put out in the paper about the issues the gates foundation was having there, it just seems 3rd world countries do things the way they do them and change the rules, or procedures whenever they want. Because they are not a wealthy country, I am sure everyone along the way requires some "incentives" to make sure papers are handled properly.
Now how does a company with not money to even pay contractors, lawyers, advisors, etc, have money to provide incentives to people in the approval chain in Africa?
AI
